Novartis

Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study
Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study
Fierce Pharma
Novartis
Kymriah
pricing
Flag link:
Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
Forbes
Novartis
drug pricing
Kymriah
Flag link:
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
GSK
R&D
Pharma CEOs
Emma Walmsley
Advair
Novartis
Sandoz
Gilead Sciences
HIV
Flag link:
FDA rejects Novartis’ Advair generic, leaving GSK without rival
FDA rejects Novartis’ Advair generic, leaving GSK without rival
Drug Delivery Business News
FDA
Novartis
Advair
generics
GSK
Sandoz
Flag link:
Pfizer's manufacturing fix clears path for Momenta's Copaxone generic
Pfizer's manufacturing fix clears path for Momenta's Copaxone generic
Biopharma Dive
Pfizer
drug manufacturing
generics
Momenta Pharmaceuticals
Copaxone
Novartis
Flag link:
Joe Jiménez, Novartis outgoing CEO, describes group’s strategy
Joe Jiménez, Novartis outgoing CEO, describes group’s strategy
GoinPharma
Joe Jimenez
Novartis
Pharma CEOs
Flag link:
Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics
Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics
Endpoints
Novartis
dwarfism
infigratinib
BridgeBio
Flag link:
FDA approves Novartis-acquired Lutathera for certain gut cancers
FDA approves Novartis-acquired Lutathera for certain gut cancers
Biopharma Dive
Novartis
FDA
Lutathera
Flag link:
Pharma gets a seat at the table at private dinner with Trump at Davos
Pharma gets a seat at the table at private dinner with Trump at Davos
Stat
Donald Trump
pharma industry
Vas Narasimhan
Novartis
Werner Baumann
Bayer
Flag link:
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Endpoints
Novartis
Lutathera
FDA
neuroendocrine tumors
Flag link:
Novartis move signals further gene therapy resurgence
Novartis move signals further gene therapy resurgence
EP Vantage
Novartis
gene therapy
Spark Therapeutics
CAR-T
Luxturna
Flag link:
Here is the salary of new Novartis CEO Vas Narasimhan
Here is the salary of new Novartis CEO Vas Narasimhan
GoinPharma
executive pay
Novartis
Vas Narasimhan
Flag link:
Spark licenses blindness gene therapy rights outside U.S. to Novartis
Spark licenses blindness gene therapy rights outside U.S. to Novartis
Yahoo/Reuters
Spark Therapeutics
Novartis
Luxturna
gene therapy
Flag link:
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
NASDAQ.com
Novartis
earnings
Cosentyx
Entresto
Flag link:
Big day looming, Novartis’ new CEO Vas Narasimhan readies his jump into a marketing melee
Big day looming, Novartis’ new CEO Vas Narasimhan readies his jump into a marketing melee
Endpoints
Novartis
Pharma CEOs
Vas Narasimhan
Joe Jimenez
Flag link:
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Fierce Pharma
Novartis
Arzerra
Genmab
CLL
chronic lymphocytic leukemia
Flag link:
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Endpoints
Novartis
Biocon
drug development
biosimilars
Flag link:
Novartis aims for US approval of Humira biosimilar
Novartis aims for US approval of Humira biosimilar
Biopharma Dive
Novartis
Humira
biosimilars
AbbVie
Sandoz
Flag link:
Novartis goes 2-0 against J&J in psoriasis
Novartis goes 2-0 against J&J in psoriasis
Biopharma Dive
Novartis
JNJ
psoriasis
Cosentyx
Stelara
Flag link:
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Yahoo/Zacks.com
Novartis
psoriasis
Cosentyx
biosimilars
ankylosing spondylitis
Flag link:

Pages